BOSTON — Moderna announced Thursday morning its COVID-19 vaccine is 96% effective in teenagers ages 12 to 17. This was data released from the company’s first-quarter earnings.
Officials added that initial analysis of its Phase 2/3 TeenCOVE study of mRNA-1273 in adolescents ages 12 to 17 shows that the vaccine effectiveness against COVID-19 was up to 96%. Overall, the mRNA-1273 was generally well tolerated with no serious safety concerns.
The biotechnology company released a statement on the full report, saying:
“In the first quarter, the Moderna team delivered on its supply commitments to many governments and helped protect more than 100 million people. This accomplishment translated into our first profitable quarter in the company’s history, after 10 years of scientific innovation and several billion dollars invested to make our mRNA platform a reality,” said Stéphane Bancel, Chief Executive Officer of Moderna.
Bancel added that they plan to increase the company’s base plan for 2021 to 800 million doses of their vaccine but are working to get close to 1 billion doses in 2021.
For a full release on Moderna’s first-quarter earnings, click here.
Download the free Boston 25 News app for up-to-the-minute push alerts
>> Complete Covid-19 vaccine coverage
RESOURCES:
- Complete local and national coronavirus coverage here
- Follow us on Facebook and Twitter | Watch Boston 25 NOW